
VYNT
Healthcare · Biotechnology · $1.2M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 21, 2023 | After the close | — | -0.26 | — |
| Jun 30, 2023 | Before the open | — | -0.72 | — |
| Mar 31, 2023 | After the close | -0.61 | -0.72 | -18.0% |
| Nov 15, 2022 | Before the open | -0.70 | -0.59 | +15.7% |
| Aug 22, 2022 | After the close | -0.75 | -1.00 | -33.3% |
| May 16, 2022 | Before the open | -0.80 | -1.60 | -100.0% |
| Mar 30, 2022 | Before the open | -0.80 | -0.20 | +75.0% |
| Nov 11, 2021 | After the close | -0.75 | -0.75 | 0.0% |
| Aug 16, 2021 | After the close | — | -0.14 | — |
| May 17, 2021 | After the close | — | -4.20 | — |
| Mar 31, 2021 | Before the open | — | -1.05 | — |
| Nov 2, 2020 | After the close | — | -0.58 | — |
| Aug 13, 2020 | After the close | — | -0.82 | — |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett…
| May 29, 2020 |
| After the close |
| 0.60 |
| -4.20 |
| -800.0% |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.80 | — |
| Nov 19, 2019 | After the close | -0.30 | -2.38 | -693.3% |
| Aug 19, 2019 | After the close | -0.05 | -0.30 | -500.0% |
| Apr 16, 2019 | Before the open | -24.00 | -21.00 | +12.5% |
| Mar 31, 2019 | Time not confirmed | -4.80 | -0.91 | +81.0% |
| Nov 19, 2018 | After the close | -25.50 | -46.50 | -82.4% |
| Aug 14, 2018 | Before the open | -23.25 | -19.50 | +16.1% |
| Apr 2, 2018 | After the close | -16.50 | -54.00 | -227.3% |